Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20425759 | 1.00 | ACHE (0.65) | ACHECYP1A2CYP2A6 | |
| SCHEMBL2200368 | 0.93 | ACHE (0.55) | ACHECYP1A2CYP2A6 | |
| SCHEMBL29463725 | 0.93 | ACHE (0.55) | ACHECYP1A2CYP2A6 | |
| Perchlorate SCHEMBL10009695 | 0.87 | ACHE (0.49) | ACHECYP1A2CYP2A6 | |
| Perchlorate SCHEMBL29876325 | 0.87 | ACHE (0.49) | ACHECYP1A2CYP2A6 | |
| SCHEMBL20425740 | 0.83 | ACHE (0.46) | ACHECYP1A2CYP2A6 | |
| SCHEMBL29890052 | 0.83 | ACHE (0.46) | ACHECYP1A2CYP2A6 | |
| SCHEMBL3972008 | 0.78 | ACHE (0.74) | ACHE | |
| SCHEMBL29411838 | 0.78 | ACHE (0.74) | ACHE | |
| SCHEMBL18292171 | 0.75 | TERT (0.40) | ACHECYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739648-A1 | PHOTOISOMERIZATION OF GERANIAL AND NERAL | BASF SE (DE) | 2026-05-13 | — | — | EP | claimed |
| WO-2025079090-A1 | SUBSTITUTED 4-HETEROATOM-ISOQUINOLONE COMPOUNDS, PROCESS OF PREPARATION AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2025-04-17 | — | — | WO | claimed |
| WO-2025011972-A1 | PHOTOISOMERIZATION OF GERANIAL AND NERAL | BASF SE (DE) | 2025-01-16 | — | — | WO | claimed |
| WO-2024103022-A1 | POLYDOPAMINE ENCAPSULATED MATERIALS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-16 | — | — | WO | claimed |
| EP-4739648-A1 | PHOTOISOMERIZATION OF GERANIAL AND NERAL | BASF SE (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-20250221966-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025079090-A1 | SUBSTITUTED 4-HETEROATOM-ISOQUINOLONE COMPOUNDS, PROCESS OF PREPARATION AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2025-04-17 | — | — | WO | disclosed |
| CN-119144609-B | Nucleic acid composition for detecting canine coronavirus and canine parvovirus, kit and application | 上海基灵生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025026536-A1 | A METHOD FOR PHOTOCATALYTIC DOPING OF AN ORGANIC SEMICONDUCTOR | N-INK AB (SE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025011972-A1 | PHOTOISOMERIZATION OF GERANIAL AND NERAL | BASF SE (DE) | 2025-01-16 | — | — | WO | disclosed |
| CN-119144609-A | Nucleic acid composition for detecting canine coronavirus and canine parvovirus, kit and application | 上海基灵生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118843613-A | RXFP1 agonists | 百时美施贵宝公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4422746-A1 | RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024103022-A1 | POLYDOPAMINE ENCAPSULATED MATERIALS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20230398527-A1 | ACRIDINIUM-BASED PHOTOREDOX CATALYSTS, SYNTHESIS AND USE THEREOF IN OXIDATIVE CLEAVAGE OF C-O BONDS | UNIV RENNES (FR) | 2023-12-14 | — | — | US | disclosed |
| WO-2023076626-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398527-A1 | ACRIDINIUM-BASED PHOTOREDOX CATALYSTS, SYNTHESIS AND USE THEREOF IN OXIDATIVE CLEAVAGE OF C-O BONDS | PPOX, DCXR, LPO | ACHE 899/4885CYP1A2 237/4885CYP2A6 1731/4885 |
| US-20250221966-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | ACHE 4776/4885CYP1A2 1125/4885CYP2A6 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.